Table 1 Comparison of characteristics of patients with a history of myocardial infarction in different trials.
| RACPC angina, 1996–2002 (n = 2366) | PEACE, 1996–2000 (n = 4132) | ACTION, 1996–1998 (n = 3840) | TNT, 1998–1999 (n = 5006) | |
|---|---|---|---|---|
| Baseline risk factors | ||||
| Age | 62 (11) | 64 (8) | 63.4 (9.3) | 61 (9) |
| Females | 43% | 17% | 21% | 19% |
| Non‐white ethnicity | 24% | 7% of cohort | 2% of cohort | 6% |
| Diabetes | 17% | 16% | 14% | 15% |
| Current smoker | 23% | 15% | 17% | 13% |
| Systolic blood pressure | 147 (22) | 133 (17) | 138 (19) | 131 (17) |
| Cardiac history | ||||
| Angina | 100% | 71% | 92% | 81% |
| MI | 0% | 56% | 50% | 58% |
| PTCA | 0% | 41% | 20%–25%* | 54% |
| CABG | 0% | 40% | — | 47% |
| Drugs | ||||
| β Blockers | 54% | 60% | 80% | — |
| Statins | 28% | 70% | 62% | — |
| Aspirin | 84% | 91% | 86% | — |
| Annual endpoint comparisons | ||||
| All‐cause mortality (95% CI)† | 3.1% (2.6 to 3.5) | 1.7% (1.5 to 1.9) | 1.5% (1.4 to 1.7) | 1.1% (1.0 to 1.3) |
| Cardiovascular mortality (95% CI)† | 1.8% (1.4 to 2.1) | 0.8% (0.6 to 0.9) | 0.8% (0.7 to 0.9) | — |
| CHD death and non‐fatal MI (95% CI)† | 2.3% (1.9 to 2.7) | 1.9% (1.6 to 2.0)‡ | 1.8% (1.6 to 2.0) § | 1.7% (1.5 to 1.9) |
ACTION, effect of long‐acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment; CABG, coronary artery bypass graft; CHD, coronary heart disease; MI, myocardial infarction; PEACE, Prevention of Events with Angiotensin‐Converting Enzyme inhibition; PTCA, percutaneous transluminal coronary angioplasty; RACPC, rapid‐access chest pain clinic; TNT, Treating to New Targets.
*Annual incidence = total incidence of events/follow‐up time.
†Range between those without and with a history of MI who had PTCA.
‡Figures are for annual cardiovascular death + nonfatal MI, so the actual figures for the endpoint are likely to be lower.
§Extracted from primary endpoint for safety (fatal + nonfatal cardiovascular events).